Semaglutide Acetate

SKU: orb1306843

Description

Semaglutide acetate is a potent, selective, and orally active GLP-1 receptor agonist with an EC50 of 6.2 pM. It is a long-acting compound used in research for type 2 diabetes, facilitating both in vitro receptor studies and in vivo investigations of glycemic control and weight management.

Research Area

Cell Biology, Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 1997361-85-9
• MW: 4174.68
• Purity: 99.45% (May vary between batches)
• Formula: C₁₈₉H₂₉₅N₄₅O₆₁
• SMILES: CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CNC=N6)N.CC(=O)O
• Target: Autophagy,Glucagon Receptor,p38 MAPK,Bcl-2 Family,IGF-1R,Apoptosis
• Solubility: DMSO:4.17 mg/mL (1 mM);H2O:< 0.05 mg/mL (insoluble)

Bioactivity

• Target IC50:
  GLP1:0.38 nM (Ki)
• In Vivo:
  METHODS: To study the antitumor activity of Semaglutide Acetate, Semaglutide (3 μmol/kg) was subcutaneously injected into nude mice with oral squamous cell carcinoma (OSCC) transplanted tumors for 3 weeks per week for 3 consecutive weeks. RESULTS: Semaglutide Acetate significantly inhibited the growth of oral squamous cell carcinoma (OSCC) xenografts in nude mice, down-regulated the proliferation markers Ki67 and PCNA, up-regulated the pro-apoptotic protein Bax and down-regulated the anti-apoptotic protein Bcl-xL. Tumor cell apoptosis was induced by activation of P38 MAPK pathway. METHODS: To investigate the effect of Semaglutide Acetate on Parkinson's disease, a mouse model of chronic MPTP-induced Parkinson's disease was induced by intraperitoneal injection of Semaglutide (25 nmol/kg) every 2 days for 30 consecutive days. RESULTS: Semaglutide Acetate improved chronic MPTP-induced Parkinson's disease and motor dysfunction in mice. Semaglutide acetate increased the number of tyrosine (TH) -positive neurons in the substantia nigra, reduced α-synuclein aggregation and glial cell activation, and decreased the level of oxidative stress marker 4-HNE. METHODS: To study the effect of Semaglutide Acetate on fatty liver disease, metabolic dysfunction associated fatty liver disease (MASLD) mice were subcutaneously injected with Semaglutide (25 μg/kg, 100 μg/kg) once a week for 11 weeks. RESULTS: Semaglutide Acetate reduced body weight, blood glucose, serum liver enzymes (ALT, AST, and AP), reduced intrahepatic triglyceride deposition, ameliorated hepatic steatosis and hepatocyte balloon-like degeneration, and down-regulated de novo lipogenesis markers Acaca and Scd1.
• In Vitro:
  METHODS: SH-SY5Y cells were treated with Semaglutide acetate (0, 1, 10, and 100 nM) for 24 hours, and cell viability was measured using MTT assay. RESULTS: Semaglutide acetate significantly increased the survival rate of SH-SY5Y cells. METHODS: SH-SY5Y cells were treated with Semaglutide acetate for 48 hours, and target protein expression was detected using Western Blot. RESULTS: Semaglutide acetate increased the expression of autophagy-related proteins such as LC3II, Atg7, Beclin-1, and P62, inhibited Bax and up-regulated Bcl-2, thereby protecting nerve cells by enhancing autophagy and inhibiting apoptosis. METHODS: Oral squamous cell carcinoma (OSCC) cells were treated with Semaglutide acetate (5-40 μM) for 48 hours, and target protein expression was detected using Western Blot. RESULTS: Semaglutide acetate up-regulated E-cadherin and down-regulated Vimentin, activated P38 MAPK signaling pathway (p-P38 expression increased), and induced cell apoptosis.

Storage & Handling

• Storage: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Semaglutide Acetate, Semaglutide Acetate(910463-68-2 Free base), GlucagonReceptor, Glucagon Receptor, GLP-1

Compound Identifiers

PubChem CID

171360195